Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071328 · ClinicalTrials.gov registry record · Early Phase 1
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
A Early Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03071328 is a Early Phase 1 study that has completed, run by Duke University. The registered enrollment target is 10 participants.
The verdict
NCT03071328, a Early Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to plan for future clinical trials in patients with metastatic urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT fluoroscopy guidance into bone, lymph node, soft tissue and liver metastases in subjects with metastatic prostate cancer, urothelial carcinoma, or renal cell carcinoma. Pre- and post-injection CT images will be obtained to determine the injection parameters needed for optimal distribution throughout metastases of a given size. A biopsy of the metastatic site will also be obtained to validate expression of the receptor CD155.
Interventions
- DRUG Isovue-M 200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-01-08 |
| Est. Completion | 2021-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03071328
The ClinicalTrials.gov registry entry for NCT03071328 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Isovue-M 200 is the first listed.
NCT03071328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03071328 about?
NCT03071328 is a clinical study titled "INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers". The purpose of this study is to plan for future clinical trials in patients with metastatic urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT fluoroscopy guidance into bone, lymph node, soft tissue and liver metastases in subjects with metastatic prostate cance...
What is the current status of trial NCT03071328?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2018-01-08. Estimated completion is 2021-04-30.
What interventions are being tested in trial NCT03071328?
The interventions under investigation include: Isovue-M 200 (DRUG).
Who is sponsoring clinical trial NCT03071328?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.